@article {7913,
	title = {Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study},
	journal = {Anticancer Research},
	volume = {27},
	year = {2007},
	note = {Cited By :5Export Date: 21 February 2017},
	month = {2007},
	pages = {4391 - 4395},
	abstract = {Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent chemoradiotherapy following induction with non-platinum chemotherapy in patients with inoperable locally advanced NSCLC. Patients and Methods: All patients with locally advanced inoperable NSCLC ECOG performance status (PS): 0-1 following staging received paclitaxel 200 mg/m2 in a 3-h infusion on day 1 and gemcitabine 1000 mg/m2 on days 1 and 8 every 21 days for two cycles. The patients with a response or stable disease (SD) continued to receive paclitaxel 60 mg/m2 weekly and radiotherapy 63 Gy given at 1.8 Gy once a day for 7 weeks. Results: Forty-three eligible patients entered the study. The median age was 63 years (range 42-76), male 93\%, IIIB 63\% and IIIA 37\%. Following induction 15 (36.5\%) of the patients responded: complete response (CR), 2\%; partial response (PR), 33\%; and 19 (46.5\%) SD. From those with SD, 7 (37\%) improved to a PR following concurrent chemoradiotherapy. With a median follow-up of 44 months (95\% CI: range 36-53) the median survival was 20.8 months (95\%c CI: range 15.4-26.3) and time-to-progression 8.4 months (95\% CI: range 6.2-10.6). The median survival of those who had improved response from SD to PR was 31.4 months (95\% CI: range 18.7-44.1) versus 20.8 months (95\% CI: range 5.5-11.3) for those who had no improvement (p=0.20). The commonest grade 3/4 toxicity in induction was neutropenia 12\% with 2 febrile neutropenic patients whereas in the concurrent chemoradiotherapy neutropenia, neurotoxicity and oesophagitis were observed in 6\% of the patients. Conclusion: Concurrent chemoradiotherapy following induction chemotherapy in patients with stage III NSCLC is feasible with reasonable efficacy and acceptable toxicity.},
	keywords = {Concurrent chemoradiotherapy, Gemcitabine, Non-operable localized NSCLC, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-37549017106\&partnerID=40\&md5=d130e55d8341621d5f79ee02f4891104},
	author = {Kosmidis, P.A. and Fountzilas, G. and Baka, S. and Samantas, E. and Dimopoulos, A.M. and Gogas, H. and Skarlos, D. and Papacostas, P. and Boukovinas, J. and Bakogiannis, Ch. and Pantelakos, P. and Athanasiou, H. and Misailidou, D. and Tsekeris, P. and N. Pavlidis}
}
